Skip to main content

Alerts

View all our safety and medicine shortage alerts and market actions (including recalls, product alerts and product corrections).

Search

9 result(s) found, displaying 1 to 9
  • More prominent warnings are being added to the Product Information and Consumer Medicine Information for all oral and injectable (systemic) fluoroquinolones to strengthen existing warnings about serious side effects.
  • Extra safety information is being added to all montelukast products to highlight the existing warnings about serious behaviour and mood-related changes
  • There have been reports of the dose counter stopping after the 10th dose and not locking after the 60th dose. If this happens, you should return the product to your place of purchase or contact Boehringer Ingelheim.
  • There are new warnings about the risks of heart attack and stroke with taking romosozumab (Evenity). The Product Information (PI) and Consumer Medicine Information (CMI) have been updated to reflect these risks.
  • Our safety advisory includes information for consumers and health professionals about low levels of nitrosamine impurity in medicines containing sitagliptin.
  • TGA investigation - potential low levels of contamination with N-nitrosovarenicline
  • Update 2 - contamination with N-nitrosodimethylamine